Illumina, Almac to Collaborate on NGS CDx Assays | GenomeWeb

NEW YORK (GenomeWeb) – Almac Diagnostics today announced a collaboration with Illumina to establish a framework for developing next-generation sequencing-based companion diagnostic assays.

Under the terms of the agreement, UK-based Almac will be able to develop NGS assays using the Illumina MiSeqDx instrument. The MiSeqDx is the first NGS instrument to be cleared by the US Food and Drug Administration for in vitro diagnostic purposes in clinical laboratories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.